Lung Non-Small Cell Carcinoma — Trials

Lung Non-Small Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1,749
Recruiting: 926
Ph III recruiting: 138
Growth YoY: +2.3%
Industry share: 44%
Top sponsor: AstraZeneca
Termination share: 39%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,045)

clinicaltrialsPublishedShowing 251–300 of 1,114 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06743581	Study of Neoadjuvant Cemiplimab and Dupilumab in Early-Stage Non-Small Cell Lung Cancer(Dupi-Cemi)	recruiting	N/A	24	Centre hospitalier de l'Université de Montréal (CHUM)OTHER	1	Aug 17, 2026	clinicaltrials
NCT06792552	A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors	recruiting	Phase 1	738	NextCure, Inc.INDUSTRY	2	Aug 17, 2026	clinicaltrials